Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

'Black Box' Warning for Antidepressants

October 25, 2004 | A version of this story appeared in Volume 82, Issue 43

FDA has ordered drug companies to add strong warnings about the use of antidepressant drugs, specifically stating that they could increase the risk of suicidal thoughts and behavior in children and adolescents. It has told manufacturers to put a "black box" warning on information sheets that go to patients and doctors. These warnings, which are written in boldface type surrounded by a black border, will warn doctors to closely monitor young patients on these medications and will state that few antidepressants have proven effective against depression in children and adolescents. The information sheets must be given to patients with every prescription. Consequently, drugmakers will have to start delivering antidepressants to pharmacies in individually boxed bottles that include the patient guides rather than in large bulk containers. These actions "reflect what we heard from our advisory committee last month, as well as what many members of the public have told us," Acting FDA Commissioner Lester M. Crawford says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.